Artificial Inclusion Bodies for Clinical Development

• DOI: 10.1002/advs.201902420
• Publication Date: 2019-11-27T08:29:46Z
• Authors: Julieta M. Sánchez; Hèctor López‐Laguna; Patricia Álamo; Naroa Serna; Alejandro Sánchez...; Verónica Nolan; Olivia Cano‐Garrido; Isolda Casanova; Ugutz Unzueta; Esther Vazquez; Ramon Mangues; Antonio Villaverde
• Keywords: Inclusion bodies; Microscale chemistry; Nanobiotechnology

Bacterial inclusion bodies (IBs) are mechanically stable protein particles in the microscale, which behave as robust, slow-protein-releasing amyloids. Upon exposure to cultured cells or upon subcutaneous intratumor injection, these materials secrete functional IB polypeptides, functionally mimicking endocrine release of peptide hormones from secretory amyloid granules. Being appealing delivery systems for prolonged drug release, development IBs toward clinical applications is, however, severely constrained by their bacterial origin and undefined protein-to-protein, batch-to-batch variable composition. In this context, de novo fabrication artificial (ArtIBs) simple, cell-free physicochemical methods, using pure components at defined amounts is proposed here. By this, resulting microparticles intriguing, chemically biomimetic that replicate relevant functionalities natural IBs, including mammalian cell penetration local remote ArtIB-forming protein. default severe regulatory issues, concept ArtIBs a novel exploitable category biomaterials biotechnological biomedical applications, simple envisaging soft developmental routes clinics.